Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond (Q38447289)

3 September 2017

1 reference

title

Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond (English)

1 reference

3 September 2017

1 reference

Frank T Zindo

1

1 reference

3 September 2017

Jacques Joubert

series ordinal

2

1 reference

3 September 2017

Sarel F Malan

series ordinal

3

1 reference

3 September 2017

language of work or name

1 reference

1 January 2015

1 reference

Future Medicinal Chemistry

3 September 2017

published in

1 reference

3 September 2017

volume

7

1 reference

3 September 2017

issue

5

1 reference

3 September 2017

page(s)

609-629

1 reference

Parkinson's disease: mechanisms and models

3 September 2017

cites work

1 reference

Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata.

21 January 2018

1 reference

Serotonin in Alzheimer-type dementia and other dementing illnesses.

21 January 2018

1 reference

The Alzheimer's disease mitochondrial cascade hypothesis: an update

21 January 2018

1 reference

Oxidative stress, glutamate, and neurodegenerative disorders

21 January 2018

1 reference

Redox-active metals, oxidative stress, and Alzheimer's disease pathology

21 January 2018

1 reference

Future treatments for Parkinson's disease: surfing the PD pipeline

21 January 2018

1 reference

The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat.

21 January 2018

1 reference

New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects.

21 January 2018

1 reference

Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior

21 January 2018

1 reference

Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.

21 January 2018

1 reference

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease

21 January 2018

1 reference

Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?

21 January 2018

1 reference

Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study

21 January 2018

1 reference

Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors

21 January 2018

1 reference

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity

21 January 2018

1 reference

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

21 January 2018

1 reference

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

21 January 2018

1 reference

A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing

21 January 2018

1 reference

Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

21 January 2018

1 reference

Monoamine oxidase expression during development and aging

21 January 2018

1 reference

21 January 2018

1 reference

Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei

21 January 2018

1 reference

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential

21 January 2018

1 reference

Inhibition of monoamine oxidase by phthalide analogues

21 January 2018

1 reference

Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria

21 January 2018

1 reference

Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases

21 January 2018

1 reference

A century of Alzheimer's disease

21 January 2018

1 reference

Monoamine oxidase: from genes to behavior

21 January 2018

1 reference

Treatment of Alzheimer's disease: current status and new perspectives.

21 January 2018

1 reference

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

21 January 2018

1 reference

Cholinergic function and Alzheimer's disease

21 January 2018

1 reference

Neurobiology of butyrylcholinesterase.

21 January 2018

1 reference

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit

21 January 2018

1 reference

Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition

21 January 2018

1 reference

Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs

21 January 2018

1 reference

Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities

21 January 2018

1 reference

Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

21 January 2018

1 reference

Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

21 January 2018

1 reference

The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions

21 January 2018

1 reference

Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine

21 January 2018

1 reference

The therapeutic potential of monoamine oxidase inhibitors

21 January 2018

1 reference

Donepezil use in Alzheimer disease

21 January 2018

1 reference

Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.

21 January 2018

1 reference

Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion

21 January 2018

1 reference

The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.

21 January 2018

1 reference

Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of [...]

21 January 2018

1 reference

A new and rapid colorimetric determination of acetylcholinesterase activity

21 January 2018

1 reference

Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.

21 January 2018

1 reference

A one-step fluorometric method for the continuous measurement of monoamine oxidase activity

21 January 2018

1 reference

Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease

21 January 2018

1 reference

Monoamine oxidase-B inhibition in Alzheimer's disease

21 January 2018

1 reference

Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil

21 January 2018

1 reference

Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).

21 January 2018

1 reference

Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs

21 January 2018

1 reference

The pharmacological manipulation of glutamate receptors and neuroprotection

21 January 2018

1 reference

Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia

21 January 2018

1 reference

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

21 January 2018

1 reference

N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease

21 January 2018

1 reference

Synthesis and biological evaluation of pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane derivatives as potential therapeutic agents in Parkinson's disease

21 January 2018

1 reference

New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities

21 January 2018

1 reference

Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities.

21 January 2018

1 reference

Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents

21 January 2018

1 reference

NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia

21 January 2018

1 reference

Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives

21 January 2018

1 reference

NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels

21 January 2018

1 reference

Neuroprotection in mice by NGP1-01 after transient focal brain ischemia.

21 January 2018

1 reference

Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs

21 January 2018

1 reference

Physicochemical prediction of a brain-blood distribution profile in polycyclic amines

21 January 2018

1 reference

Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

21 January 2018

1 reference

Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents.

21 January 2018

1 reference

Increased nigral iron content in postmortem parkinsonian brain

21 January 2018

1 reference

Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.

21 January 2018

1 reference

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

21 January 2018

1 reference

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

21 January 2018

1 reference

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

21 January 2018

1 reference

Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.

21 January 2018

1 reference

The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease

21 January 2018

1 reference

Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice

21 January 2018

1 reference

Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease

21 January 2018

1 reference

Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease

21 January 2018

1 reference

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

21 January 2018

1 reference

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

21 January 2018

1 reference

Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver

21 January 2018

1 reference

Reactive oxygen species and mitochondrial diseases

21 January 2018

1 reference

Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons

21 January 2018

1 reference

Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide

21 January 2018

1 reference

Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease

21 January 2018

1 reference

PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice

21 January 2018

1 reference

Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells

21 January 2018

1 reference

Expression, microsomal and mitochondrial activities of cytochrome P450 enzymes in brain regions from control and phenobarbital-treated rabbits.

21 January 2018

1 reference

A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs

21 January 2018

1 reference

In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.

21 January 2018

1 reference

Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.

21 January 2018

1 reference

Istradefylline: first global approval

21 January 2018

1 reference

Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders

21 January 2018

1 reference

Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease

21 January 2018

1 reference

Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.

21 January 2018

1 reference

Monoamine oxidase inhibitors and neuroprotection: a review

21 January 2018

1 reference

Adenosine A2A antagonists in Parkinson's disease: what's next?

21 January 2018

1 reference

1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases

21 January 2018

1 reference

Synthesis and biological activity of tricyclic aryloimidazo-, pyrimido-, and diazepinopurinediones

21 January 2018

1 reference

Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles

21 January 2018

1 reference

N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

21 January 2018

1 reference

Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist

21 January 2018

1 reference

1,4-Dihydropyridines--a basis for developing new drugs

21 January 2018

1 reference

Calcium channel antagonists: clinical uses--past, present and future

21 January 2018

1 reference

Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

21 January 2018

1 reference

Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist

21 January 2018

1 reference

Cocaine addiction therapy--are we partially there?

21 January 2018

1 reference

Restless legs syndrome improved by pramipexole: a double-blind randomized trial

21 January 2018

1 reference

Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents

21 January 2018

1 reference

Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists.

21 January 2018

1 reference

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

21 January 2018

1 reference

8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release

21 January 2018

1 reference

5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy

21 January 2018

1 reference

Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.15.12

1 reference

3 September 2017

1 reference